BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...

BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups...

BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic ANAHEIM, CA, April 07, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of substance use...